Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Impact of abciximab versus tirofiban on hospital length of stay for PCI patients
Autore:
Lage, MJ; Barber, BL; McCollam, PL; Bala, M; Scherer, J;
Indirizzi:
Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA Eli Lilly & CoIndianapolis IN USA 46285 Ctr, Indianapolis, IN 46285 USA Miami Univ, Dept Econ, Oxford, OH 45056 USA Miami Univ Oxford OH USA 45056 iami Univ, Dept Econ, Oxford, OH 45056 USA Centocor Inc, Malvern, PA 19355 USA Centocor Inc Malvern PA USA 19355Centocor Inc, Malvern, PA 19355 USA
Titolo Testata:
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
fascicolo: 3, volume: 52, anno: 2001,
pagine: 298 - 305
SICI:
1522-1946(200103)52:3<298:IOAVTO>2.0.ZU;2-G
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; CONGESTIVE-HEART-FAILURE; ELDERLY PATIENTS; ANGIOPLASTY; SEVERITY; OUTCOMES; STATES; CARE;
Keywords:
hospital stay; length of stay; multivariate analysis; retrospective study; sample selection model;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
39
Recensione:
Indirizzi per estratti:
Indirizzo: Barber, BL Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA Eli Lilly & Co Indianapolis IN USA 46285 napolis, IN 46285 USA
Citazione:
M.J. Lage et al., "Impact of abciximab versus tirofiban on hospital length of stay for PCI patients", CATHET C IN, 52(3), 2001, pp. 298-305

Abstract

The purpose of this retrospective study was to examine in a naturalistic setting the effect of abciximab versus tirofiban on hospital length of stay for patients undergoing percutaneous coronary intervention (PCI), Retrospective data were obtained from HCIASach's Clinical Pathways Database on 5,560PCI patients who were administered either abciximab or tirofiban. Multivariate analysis was used to control for a wide range of factors (GPIIb/IIIa selection, patient demographics, insurance provider, health conditions, admission information, and hospital characteristics) that may influence hospital length of stay. Estimation was conducted via a two-stage sample selectionmodel. After controlling for high-risk indications and sources of selection bias, results indicate that receipt of abciximab was associated with significantly shorter lengths of hospital stays compared to tirofiban (1.01 fewer days; p < 0.001). In a subgroup analysis of patients having an acute myocardial infarction (AMI; n = 2,593), receipt of abciximab was also found tobe associated with significantly shorter hospital stays compared to tirofiban (0.60 fewer days; p < 0.001). Results of this study indicate that patients who are administered abciximab versus tirofiban have significantly shorter hospital stays. This reduction in length of stay may imply potential cost offsets for PCI patients who receive abciximab. (C) 2001 Wiley-Liss, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 06:48:46